Keith Steward Email

VP Global Medical Affairs . QED Therapeutics

Current Roles

Employees:
44
Revenue:
$3.4M
About
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
QED Therapeutics Address
421 Kipling St.
Palo Alto, CA
United States
QED Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.